Recent advancements in oncology have shifted the focus toward combining targeted therapies in earlier disease stages. Specifically, the use of Saruparib in mHSPC treatment is currently under investigation in the Phase III EvoPAR-Prostate01 trial. This global, multicenter study explores the efficacy of adding a next-generation PARP inhibitor to standard androgen receptor pathway inhibitors (ARPI) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The Rationale for Saruparib in mHSPC treatment

Saruparib (AZD5305) represents a new generation of poly(ADP-ribose) polymerase inhibitors. Unlike first-generation agents that target both PARP1 and PARP2, saruparib selectively inhibits and traps PARP1. Consequently, researchers expect this selectivity to provide a wider therapeutic window. This improvement may reduce common side effects like anemia and thrombocytopenia, which often limit the use of dual PARP1/2 inhibitors. Furthermore, combining Saruparib in mHSPC treatment leverages the synergy between PARP inhibition and androgen receptor signaling blockade.

EvoPAR-Prostate01: Trial Overview and Design

The EvoPAR-Prostate01 study is a randomized, double-blind, placebo-controlled trial. It involves approximately 1,800 participants divided into two cohorts based on their homologous recombination repair mutation (HRRm) status. Specifically, participants receive either saruparib or a placebo in combination with the physician's choice of ARPI, such as abiraterone, darolutamide, or enzalutamide. The primary endpoint is radiographic progression-free survival (rPFS). Additionally, overall survival (OS) serves as a key secondary endpoint. This trial is significant for clinicians in India as it could establish a new standard of care for de novo and recurrent mHSPC patients.

Eligibility and Clinical Impact

To participate, patients must have histologically confirmed mHSPC and be suitable for ARPI therapy. However, the study excludes those with prior chemotherapy or PARP inhibitor exposure in the metastatic setting. Because mHSPC remains a high-risk disease state, early intervention with Saruparib in mHSPC treatment might delay progression to castration-resistant stages. Ultimately, the trial's results will determine if this combination therapy benefits patients regardless of their specific genetic mutation profile.

Frequently Asked Questions

What makes saruparib different from other PARP inhibitors?

Saruparib is a selective PARP1 inhibitor and trapper. While older inhibitors target both PARP1 and PARP2, saruparib's selectivity aims to minimize hematological toxicities and allow for more effective combination dosing.

Which patients are eligible for the EvoPAR-Prostate01 trial?

The trial enrolls men with metastatic hormone-sensitive prostate cancer (mHSPC). This includes both those with and without homologous recombination repair gene mutations (HRRm), provided they have not received prior chemotherapy for metastatic disease.

What are the primary goals of the EvoPAR-Prostate01 study?

The primary goal is to assess radiographic progression-free survival (rPFS). The study also evaluates overall survival and the safety profile of combining saruparib with standard androgen receptor pathway inhibitors.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

Azad AA et al. Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. Future Oncol. 2026 Apr 14. doi: 10.1080/14796694.2026.2655433. PMID: 41979035.

ClinicalTrials.gov. Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01). NCT06120491.

Armstrong AJ, et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J Clin Oncol. 2024;42(16_suppl):TPS5114.